Julen Plana-Fernandez - Publications

SEOM-GEMCAD-TTD clinical guidelines for anal cancer (2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 21, 2025

Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 30, 2025

An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 20, 2024

Negative hyperselection beyond RAS: is a key tool for choosing the optimal maintenance treatment in metastatic colorectal cancer?

Journal: Journal of gastrointestinal oncology

Published: April 17, 2024

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.

Journal: Cancers

Published: July 22, 2022

Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT.

Journal: Journal of clinical medicine

Published: April 16, 2021

Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.

Journal: JCO precision oncology

Published: December 01, 2019

Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).

Journal: The oncologist

Published: October 26, 2018

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.

Journal: Neoplasia (New York, N.Y.)

Published: April 11, 2018

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.

Journal: British journal of cancer

Published: March 27, 2018

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).

Journal: BMC cancer

Published: May 13, 2014

Results after laparoscopic liver resection: an appropriate option in malignant disease

Journal: Cirugia espanola

Published: September 13, 2012